Search results
Results from the WOW.Com Content Network
Multi-infarct dementia results from a series of small strokes affecting several brain regions. Stroke-related dementia involving successive small strokes causes a more gradual decline in cognition. [4] Dementia may occur when neurodegenerative and cerebrovascular pathologies are mixed, as in susceptible elderly people (75 years and older).
Anything that affects brain function (including stroke or other conditions that compromise blood flow) can cause cognitive issues and even dementia. Skip to main content. Sign in. Mail. 24/7 Help ...
Binswanger's disease, also known as subcortical leukoencephalopathy and subcortical arteriosclerotic encephalopathy, [1] is a form of small-vessel vascular dementia caused by damage to the white brain matter. [2] White matter atrophy can be caused by many circumstances including chronic hypertension as well as old age. [3]
Mini-stroke (transient ischemic attack) Misophonia; Mitochondrial myopathy; Mobius syndrome; Monomelic amyotrophy; Morvan syndrome; Motor neurone disease – see Amyotrophic lateral sclerosis; Motor skills disorder; Moyamoya disease; Mucopolysaccharidoses; Multifocal motor neuropathy; Multi-infarct dementia; Multiple sclerosis; Multiple system ...
Vascular or multi-infarct dementia is a subcortical dementia in which people become slower (than) forgetful,” Segil said. “Early onset diabetes (increases) cardiovascular risk with an ...
Heart problems can increase dementia risk, but a new study suggests that heparin, a common anticoagulant administered via injection, may help delay Alzheimer’s onset.
Cerebrolysin (developmental code name FPF-1070) is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).
It has been used to treat dementia and age-related cognitive impairment (such as in Alzheimer disease), [1] as well as to aid in recovery after stroke.. A systematic review published in 1994 found little evidence to support the use of ergoloid mesylates, concluding only that potentially effective doses may be higher than those currently approved in dementia treatment.